Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

RxMine

financed

Closed

A simple blood test to choose the best treatment for each patient with depressio...

A simple blood test to choose the best treatment for each patient with depression. Major depressive disorder affects around 300M people globally and is the second leading cause of disability, with up to 14 years of life lost per patient and an annual burden of up to €170 billion to the EU. Despite numerous avail... see more

31/05/2025

GENETIKAPLUS LTD

4M€

Project Budget: 4M€

Project leader

GENETIKAPLUS LTD No se ha especificado una descripción o un objeto social para esta compañía.

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2025-05-31

HORIZON-EIC-2022-ACCELERATORCHALLENGES-02: EIC Accelerator Challenge: Technolo... Scope:EIC Accelerator Challenge: Technologies for ‘Fit for 55’

I+D

Cerrada does 3 years

0% 70% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

GENETIKAPLUS LTD

2.50M€ | Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 32 months Date Start: 2022-09-15
End date: 2025-05-31

Project leader

GENETIKAPLUS LTD No se ha especificado una descripción o un objeto social para esta compañía.

Project Budget 4M€

participation deadline Sin fecha límite de participación.

Project description Major depressive disorder affects around 300M people globally and is the second leading cause of disability, with up to 14 years of life lost per patient and an annual burden of up to €170 billion to the EU. Despite numerous available drugs, 75% of patients do not receive adequate treatment, 63% try multiple medications, and a third do not respond after two rounds of treatment. This trial-and-error approach is destructive to patients, time-consuming for physicians and expensive to health care systems. RxMine revolutionizes this process by combining innovative stem cell technology, genetics, neurobiology, high-throughput screening and machine learning to test multiple antidepressants and screen drug effects using a patient-specific brain-in-a-dish model. RxMine identifies the optimal antidepressant for each patient and potentially reduces hospitalizations by 89%, emergency-room visits by 71% and depression related healthcare costs by 40% with savings up to €6,000 per patient per year.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers